{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,23]],"date-time":"2025-08-23T05:14:34Z","timestamp":1755926074185,"version":"3.37.3"},"reference-count":34,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2017,3,22]],"date-time":"2017-03-22T00:00:00Z","timestamp":1490140800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Birth Defects Research"],"published-print":{"date-parts":[[2017,4,17]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The purpose of these studies was to evaluate the effects of evacetrapib on male and female fertility and on embryo\u2010fetal development (EFD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Evacetrapib, a potent and selective inhibitor of cholesteryl ester transfer protein (CETP), was administered daily by oral gavage starting 2 weeks (for female) or 4 weeks (for male) before mating, during cohabitation, and until necropsy in the male rat fertility study or through gestation day (GD) 17 in the female rat combined fertility\/EFD study. For rabbit EFD studies, animals were dosed from GDs 7 to 19 or from 1 week before mating through GD 19. Dose levels of evacetrapib ranged from 60 to 600 mg\/kg for rats and from 1 to 100 mg\/kg\/day for rabbits.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Parental findings in rats included decreased body weight and food consumption and moribund euthanasia in animals given 600 mg\/kg\/day and decreased food consumption at 300 mg\/kg\/day. There were no adverse effects on estrus cycling, fertility indices, sperm parameters, maternal reproductive parameters, male reproductive tissue, or fetal viability, growth, or external\/visceral morphology. An increase in the incidence of 14th rudimentary ribs, a minor, transient variation considered nonadverse, was the only significant developmental finding in rats given 600 mg\/kg\/day. Slight decreases in body weight and food consumption at 100 mg\/kg\/day were the only maternal effects observed in rabbits with no adverse developmental effects noted.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>No adverse effects on fertility or EFD were observed in rats at doses up to 600 mg\/kg\/day and no adverse effects on EFD were noted in rabbits at doses up to 100 mg\/kg\/day. Birth Defects Research 109:513\u2013527, 2017. \u00a9 2017 Wiley Periodicals, Inc.<\/jats:p><\/jats:sec>","DOI":"10.1002\/bdr2.1022","type":"journal-article","created":{"date-parts":[[2017,3,23]],"date-time":"2017-03-23T08:07:55Z","timestamp":1490256475000},"page":"513-527","source":"Crossref","is-referenced-by-count":2,"title":["Fertility and Embryo\u2010Fetal Development Assessment in Rats and Rabbits with Evacetrapib: A Cholesteryl Ester Transfer Protein Inhibitor"],"prefix":"10.1002","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0139-9693","authenticated-orcid":false,"given":"William J.","family":"Breslin","sequence":"first","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kim G.","family":"Hilbish","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen A.","family":"Cannady","sequence":"additional","affiliation":[{"name":"Lilly Research Laboratories Lilly Corporate Center Indianapolis Indiana"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tammy L.","family":"Edwards","sequence":"additional","affiliation":[{"name":"Charles River Laboratories Ashland Ohio"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,3,22]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrb.21089"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040583"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1194\/jlr.M018069"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/bdrc.20027"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.1986.03380200073024"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61350-5"},{"key":"e_1_2_6_8_1","unstructured":"Crestor.2016.Full prescribing information Crestor (rosuvastatin). Reference ID 3937746. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2016\/021366s033lbl.pdf."},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.3109\/10520292609115636"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.3109\/10408444.2011.653487"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1080\/00401706.1964.10490181"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.2307\/2528490"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0305-0491(98)10038-X"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/0305-0491(82)90252-8"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1096-4959(03)00046-0"},{"key":"e_1_2_6_16_1","first-page":"468","volume-title":"Nonparametric Statistical Methods","author":"Hollander M","year":"1999"},{"key":"e_1_2_6_17_1","unstructured":"International Conference on Harmonisation (ICH).2005.International Conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. Detection of toxicity to reproduction for medicinal products and toxicity to male fertility S5(R2). Available at:http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Safety\/S5\/Step4\/S5_R2__Guideline.pdf."},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1080\/01621459.1952.10483441"},{"key":"e_1_2_6_19_1","unstructured":"Lipitor.2015.Full prescribing information Lipitor (atorvastatin). Reference ID 3714589. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/020702s065lbl.pdf."},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2011.1649"},{"key":"e_1_2_6_21_1","unstructured":"Praluent.2015.Full prescribing information Praluent (alirocumab). Reference ID 3797282. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125559Orig1s000lbledt.pdf."},{"key":"e_1_2_6_22_1","unstructured":"Repatha.2015.Full prescribing information Repatha (evolocumab). Reference ID 3812424. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/125522s000lbl.pdf."},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2012.08.962"},{"key":"e_1_2_6_24_1","first-page":"215","volume-title":"One\u2010Way Classifications; Analysis of Variance. Statistical Methods","author":"Snedecor GW","year":"1980"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/tcm.1770040203"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/jphp.12287"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2014.12.017"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejphar.2014.07.048"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1248\/bpb.24.579"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1002\/jat.2550080205"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1749-6632.1965.tb12260.x"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.ATV.8.6.737"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1002\/tera.1420060210"},{"key":"e_1_2_6_34_1","unstructured":"Zetia.2012.Full prescribing information Zetia (ezetimibe). Reference ID 3076051. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/021445s033lbl.pdf."},{"key":"e_1_2_6_35_1","unstructured":"Zocor.2015.Full prescribing information Zocor (simvastatin). Reference ID 3695644. Available at:http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2015\/019766s093lbl.pdf."}],"container-title":["Birth Defects Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fbdr2.1022","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bdr2.1022","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T18:56:20Z","timestamp":1696618580000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/bdr2.1022"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,3,22]]},"references-count":34,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2017,4,17]]}},"alternative-id":["10.1002\/bdr2.1022"],"URL":"https:\/\/doi.org\/10.1002\/bdr2.1022","archive":["Portico"],"relation":{},"ISSN":["2472-1727","2472-1727"],"issn-type":[{"type":"print","value":"2472-1727"},{"type":"electronic","value":"2472-1727"}],"subject":[],"published":{"date-parts":[[2017,3,22]]}}}